article

Regenerative medicine: a manufacturing overview

The field of regenerative medicine – an area promising a revolution in 21st century healthcare – has been enabled by rapid scientific advancements in recent years. There is a growing need for a new generation of therapeutic products, made more severe by the global shortages of organs available for transplantations. However, before regenerative therapies can start playing a significant role in modern medicine, the industry must provide solutions to several key manufacturing challenges. Here, Maciej Nakoniecznik provides an overview of what the future holds for regenerative medicine.

Regenerative medicine

THERE ARE currently approximately 6,000 people awaiting lifesaving organ transplantations on the UK Transplant waiting list. In 2018/19, over 400 people died in the UK due to organ shortages.1 This figure is likely to be significantly higher this year, as safety restrictions introduced due to the COVID-19 pandemic saw the number of transplants performed between April and June plummet by over 50 percent compared to the same period last year.2 In the US, a steep growth in the number of transplants has been observed since 2013, with the number of patients on the transplant waiting list falling steadily during that period.3 However, over 112,000 people remained on the waiting list in September 2019, with more than 7,000 deaths attributed to organ shortages every year across the country.4











To read this article in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

Send this to a friend